<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29267608</article-id><article-id pub-id-type="pmc">5731312</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Evaluation of Nosocomial Infections in Pediatric Patients with
Extracorporeal Membrane Oxygenation Support</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ayy&#x00131;ld&#x00131;z</surname><given-names>Pelin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Kasar</surname><given-names>Taner</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ozturk</surname><given-names>Erkut</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yildiz</surname><given-names>Okan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ozturk</surname><given-names>Serpil</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ergul</surname><given-names>Yakup</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haydin</surname><given-names>Sertac</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Guzeltas</surname><given-names>Alper</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Pediatric Cardiology, Istanbul Saglik Bilimleri
University Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education
and Research Hospital, Istanbul, Turkey.</aff><aff id="aff2">
<label>2</label> Department of Cardiovascular Surgery, Istanbul Saglik Bilimleri
University Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education
and Research Hospital, Istanbul, Turkey.</aff><aff id="aff3">
<label>3</label> Department of Infectious Diseases, Istanbul Saglik Bilimleri
University Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education
and Research Hospital, Istanbul, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Pelin Ayy&#x00131;ld&#x00131;z, Department of
Pediatric Cardiology - Saglik Bilimleri University Turkey Istanbul, Mehmet Akif
Ersoy Thoracic and Cardiovascular Surgery Education and Research Hospital
&#x00130;stasyon Mahallesi &#x00130;stanbul Caddesi Bezirganbah&#x000e7;e Mevki 34303
K&#x000fc;&#x000e7;&#x000fc;k&#x000e7;ekmece - &#x00130;stanbul, Turkey. E-mail:
<email>pelinhoglu2@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2017</year></pub-date><volume>32</volume><issue>6</issue><fpage>468</fpage><lpage>474</lpage><history><date date-type="received"><day>06</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>8</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Extracorporeal membrane oxygenation (ECMO) has become a standard technique
over the past few decades in intensive care unit (ICU).</p></sec><sec><title>Objective</title><p>A review of pediatric patients who received ECMO support in the pediatric
cardiac ICU was conducted to determine the incidence, risk factors and
causal organisms related to acquired infections and assess the survival
rates of ECMO patients with nosocomial infections.</p></sec><sec><title>Methods</title><p>Sixty-six patients who received ECMO support in the pediatric cardiac ICU
between January 2011 and June 2014 were included in the study. Demographic,
echocardiographic, hemodynamic features and surgical procedures were
reviewed.</p></sec><sec><title>Results</title><p>Sixty-six patients received a total of 292.5 days of venoarterial ECMO
support. Sixty were postoperative patients. Forty-five patients were weaned
from ECMO support with an ECMO survival rate of 68.2%. The rate of infection
was 116.2/1000 ECMO days. Prolonged ICU stay, duration of ventilation and
ECMO were found associated with development of nosocomial infection and only
the duration of ECMO was an independent risk factor for nosocomial
infections in ECMO patients.</p></sec><sec><title>Conclusion</title><p>The correction of the underlying process leading to ECMO support and
shortening the length of ECMO duration together with stricter application of
ECMO indications would improve the infection incidence and hospital
surveillance of the patient group.</p></sec></abstract><kwd-group><kwd>Extracorporeal Membrane Oxygenation</kwd><kwd>Cross Infection</kwd><kwd>Child</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACT</td><td align="left" rowspan="1" colspan="1">= Activated clotting time</td></tr><tr><td align="left" rowspan="1" colspan="1">aPTT</td><td align="left" rowspan="1" colspan="1">= Activated partial thromboplastin time</td></tr><tr><td align="left" rowspan="1" colspan="1">BSI</td><td align="left" rowspan="1" colspan="1">= Blood stream infections</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN</td><td align="left" rowspan="1" colspan="1">= Blood urea nitrogen</td></tr><tr><td align="left" rowspan="1" colspan="1">CDC</td><td align="left" rowspan="1" colspan="1">= Centers for Disease Control</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">= C-reactive protein</td></tr><tr><td align="left" rowspan="1" colspan="1">ECMO</td><td align="left" rowspan="1" colspan="1">= Extracorporeal membrane oxygenation</td></tr><tr><td align="left" rowspan="1" colspan="1">ELSO</td><td align="left" rowspan="1" colspan="1">= Extracorporeal Life Support Organization</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="left" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" rowspan="1" colspan="1">RACHS-1</td><td align="left" rowspan="1" colspan="1">= Risk-Adjusted Congenital Heart Surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">RTI</td><td align="left" rowspan="1" colspan="1">= Respiratory tract infection</td></tr><tr><td align="left" rowspan="1" colspan="1">SWI</td><td align="left" rowspan="1" colspan="1">= Sternal wound infections</td></tr><tr><td align="left" rowspan="1" colspan="1">UTI</td><td align="left" rowspan="1" colspan="1">= Urinary tract infection</td></tr><tr><td align="left" rowspan="1" colspan="1">VA</td><td align="left" rowspan="1" colspan="1">= Venoarterial</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>The use of extracorporeal membrane oxygenation (ECMO) has become a standard technique
to provide temporary respiratory and cardiovascular support to pediatric and adult
patients over the past few decades<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Despite the efficacy, significant associated risks including
infections are present<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The
cannulation of major vessels provides entry for infectious agents along with
additional invasive devices such as urinary catheters, endotracheal tubes, dialysis
and central venous catheters, which further increase the risk of nosocomial
infection in patients on ECMO<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>ECMO support has been used in our pediatric cardiology and cardiovascular intensive
care unit (ICU) and the patient records who have received ECMO were retrospectively
collected. This study aims to determine the incidence, risk factors and causal
organisms related to acquired infections in pediatric patients who received ECMO and
assess the survival rates of ECMO patients with nosocomial infections.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The study was a retrospective cohort study and approved by the Institutional Review
Board. Written consent was taken from the parents.</p><p>Sixty-six patients who received ECMO support in the pediatric cardiac ICU at the
Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center between January 2011
and June 2014 were included in this retrospective study. The medical records were
retrospectively reviewed from database of the hospital and incomplete data was
fulfilled from individual chart review; age, sex, underlying medical condition,
length of stay in the pediatric ICU, length of hospitalization, duration of
ventilation, indication for ECMO support, duration of ECMO support, duration of post
ECMO ventilation, empiric antibiotics within first 24 hours of ECMO, ECMO-related
infections, type of infection and causative agents, pH, C-reactive protein (CRP),
blood urea nitrogen (BUN), lactate before ECMO support, and final outcome were
recorded. During the study period, there was no defined protocol for antibiotic
prophylaxis for ECMO in our clinic.</p><p>A hospital-acquired infection was defined as an infection that was not present, nor
an extension of an infection present, on admission to the hospital. All
hospital-acquired infections including blood stream infections (BSI), respiratory
tract infection (RTI), urinary tract infection (UTI) and sternal wound infections
(SWI) of the patients were recorded and Centers for Disease Control and Prevention
(CDC) criteria were used as standard definitions for ECMO related hospital-acquired
infections<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Nosocomial
infections that occurred 24 h after initiation and 48 h after discontinuation of
ECMO were defined as ECMO-related nosocomial infections<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The percentage of patients who survived after ECMO
discontinuation to the total number of patients who received ECMO was defined as the
ECMO survival rate, and the percentage of patients who survived to discharge from
hospital to the total number of patients who received ECMO was defined as the
overall survival rate<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>All patients were intubated before ECMO. Since our patient population was mainly
postoperative cardiac patients, they all underwent venoarterial (VA) cannulation.
DLP (Medtronic<sup>&#x000ae;</sup>, Inc., Minneapolis, MN, USA) arterial and venous
ECMO cannula were used for ECMO cannulation for all patients.</p><p>A central venous line and a nasogastric tube were placed before ECMO was initiated.
Medos Deltastream<sup>&#x000ae;</sup> System has been in use for ECMO support in our
ICU unit and after November 2012, Medos Deltastream<sup>&#x000ae;</sup> DC system
with DP2 pump head (MedosAG, Stolberg, Germany) was switched to the Medos
Deltastream<sup>&#x000ae;</sup> MDC system with DP3 pump head (MedosAG, Stolberg,
Germany). Continuous intravenous heparin infusion was started and titrated at a
dosage adequate to keep activated clotting time (ACT) around 180-200 sec and
activated partial thromboplastin time (aPTT) in a range of 60-80 sec. The ECMO pump
flow started at a rate of 100 ml/kg/min but higher flow of 150-200 ml/kg/min was
preferred in patients with single ventricle and after shunt operations with
sternotomy. The flow rate was set again after the correction of end-organ perfusion,
lactic acidosis, arterial blood gases and an increase in systemic venous oxygen
saturation was established. Urine cultures were obtained weekly and when clinically
indicated. Patients were removed from ECMO when their cardiac or pulmonary status
improved or they were decannulated because of irreversible disease as severe
neurologic injury<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><sec><title>Statistical Analysis</title><p>All analyses were performed using SPSS 15.0 for Windows (SPSS, Chicago, IL, USA).
The statistical significance of continuous variables was determined using
nonparametric tests (the Mann-Whitney U-test), and categorical variables were
analyzed with Fisher's exact test. A value of <italic>P</italic>&#x0003c;0.05 was
considered statistically significant. The median (maximum-minimum) of the
variables was reported. After univariate analysis with selected variables, a
logistic regression model was used for multivariate analysis to determine the
independent predictive factors of ECMO-related infections.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 66 patients received a total of 292.5 days of VA-ECMO support in the
pediatric cardiac ICU. Sixty were postoperative patients, and six patients were
internalized by different indications. The Risk-Adjusted Congenital Heart Surgery
(RACHS-1) category of the operated patients were median 3 (range 2-6) whereas the
O`Brian classification of the operated patients were median 3 (range 1-5).
Twenty-five patients were newborns (37.8%), 37 were infants (56%), three were
children older than two years of age (4.5%) and one was an adolescent (1.5%). The
indications for ECMO were cardiac arrest in 21 patients, hypotension resistant to
medication in 36 patients, failure to be separated from cardiopulmonary bypass in
four patients, pulmonary hypertensive crisis in two patients, and other in three
patients.</p><p>Forty-five patients were weaned from ECMO support with an ECMO survival rate of
68.2%. The overall survival rate was 33.3%. All but two deaths occurred more than 48
h after separation from ECMO (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Comparison of patient characteristics with and without infectious
complications.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Total (n=66)</th><th align="center" rowspan="1" colspan="1">Non-infected (n=38)</th><th align="center" rowspan="1" colspan="1">Infected (n=28)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (month)</td><td align="center" rowspan="1" colspan="1">4 (0.03-240)</td><td align="center" rowspan="1" colspan="1">5.2 (0.03-108)</td><td align="center" rowspan="1" colspan="1">1.5 (0.03-240)</td><td align="center" rowspan="1" colspan="1">0.256</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (male/female)</td><td align="center" rowspan="1" colspan="1">38/28</td><td align="center" rowspan="1" colspan="1">24/14</td><td align="center" rowspan="1" colspan="1">14/12</td><td align="center" rowspan="1" colspan="1">0.799</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative ECMO (n)</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">0.693</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ECMO (day)</td><td align="center" rowspan="1" colspan="1">4 (1-13)</td><td align="center" rowspan="1" colspan="1">3.5 (1-8)</td><td align="center" rowspan="1" colspan="1">4 (1-13)</td><td align="center" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" rowspan="1" colspan="1">pH</td><td align="center" rowspan="1" colspan="1">7.18 (6.9-7.5)</td><td align="center" rowspan="1" colspan="1">7.14 (6.9-7.5)</td><td align="center" rowspan="1" colspan="1">7.19 (6.9-7.43)</td><td align="center" rowspan="1" colspan="1">0.410</td></tr><tr><td align="left" rowspan="1" colspan="1">Lactate (mmol/L)</td><td align="center" rowspan="1" colspan="1">9.8(1.6-129)</td><td align="center" rowspan="1" colspan="1">10.4(1.6-129)</td><td align="center" rowspan="1" colspan="1">9 (3.3-17.6)</td><td align="center" rowspan="1" colspan="1">0.284</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dl)</td><td align="center" rowspan="1" colspan="1">17 (0.5-185)</td><td align="center" rowspan="1" colspan="1">19.4 (0.6-116)</td><td align="center" rowspan="1" colspan="1">17 (0.5-185)</td><td align="center" rowspan="1" colspan="1">0.870</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mg/dl)</td><td align="center" rowspan="1" colspan="1">15(2-40)</td><td align="center" rowspan="1" colspan="1">15(2-38)</td><td align="center" rowspan="1" colspan="1">14.5(2-40)</td><td align="center" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotics on ECMO day 1</td><td align="center" rowspan="1" colspan="1">65 (98%)</td><td align="center" rowspan="1" colspan="1">37 (97,4%)</td><td align="center" rowspan="1" colspan="1">28 (100%)</td><td align="center" rowspan="1" colspan="1">0.287</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ICU stay (day)</td><td align="center" rowspan="1" colspan="1">14.5 (2-114)</td><td align="center" rowspan="1" colspan="1">11.5 (2-114)</td><td align="center" rowspan="1" colspan="1">17 (7-81)</td><td align="center" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ventilation (day)</td><td align="center" rowspan="1" colspan="1">12 (1-114)</td><td align="center" rowspan="1" colspan="1">9 (1-114)</td><td align="center" rowspan="1" colspan="1">14.5 (3-66)</td><td align="center" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" rowspan="1" colspan="1">Outcome</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">ECMO survival</td><td align="center" rowspan="1" colspan="1">45 (68.2%)</td><td align="center" rowspan="1" colspan="1">24 (63.2%)</td><td align="center" rowspan="1" colspan="1">21 (75%)</td><td align="center" rowspan="1" colspan="1">0.424</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall survival</td><td align="center" rowspan="1" colspan="1">22 (33.3%)</td><td align="center" rowspan="1" colspan="1">11 (28.9%)</td><td align="center" rowspan="1" colspan="1">11 (39.3%)</td><td align="center" rowspan="1" colspan="1">0.435</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BUN=blood urea nitrogen; CRP=C-reactive protein; ICU=intensive care
unit</p></fn></table-wrap-foot></table-wrap><p>A total of 28 patients out of the 66 patients experienced 34 infectious episodes
during ECMO support. Culture-positive infections were detected at a single site in
22 patients, and multiple sites in six patients. There were 13 (37.2%) BSI, 10
(29.4%) RTI, 9 (25.7%) UTI, and 2 SWI (5.7%) (<xref ref-type="table" rid="t2">Table
2</xref>). The nosocomial infection rate was 116.2/1000 ECMO days.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>The characteristics of patients who had culture positive nosocomial
infection.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient n&#x000ba;</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Number of sites of infection</th><th align="center" rowspan="1" colspan="1">Site of positivity</th><th align="center" rowspan="1" colspan="1">Microorganism</th><th align="center" rowspan="1" colspan="1">Days of ECMO</th><th align="center" rowspan="1" colspan="1">Antibiotics at ECMO initiation</th><th align="center" rowspan="1" colspan="1">ECMO survival</th><th align="center" rowspan="1" colspan="1">Result</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1">MRCNS</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">10 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">UTI</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1 day</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1">MSSA</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">10 days</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">BSI, RTI</td><td align="center" rowspan="1" colspan="1"><italic>Klebsiella</italic></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">18 days</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">BSI, RTI</td><td align="center" rowspan="1" colspan="1"><italic>Acinetobacteria</italic></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">UTI</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic></td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">24 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Pseudomonas</italic></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1">MRCNS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">21 day</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">BSI UTI</td><td align="center" rowspan="1" colspan="1"><italic>Micrococcus Candida</italic></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">20 years</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1">MSCNS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">28 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1"><italic>Corynebacterium bovis</italic></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">16 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1"><italic>Enterobacteria cloacae</italic></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">3 days</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">BSI Tissue</td><td align="center" rowspan="1" colspan="1">MRCNS <italic>Candida Alb</italic></td><td align="center" rowspan="1" colspan="1">3,5</td><td align="center" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">13 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1">MSCNS</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">1 month</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1"><italic>Stenotrophomonas</italic></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">14 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Pseudomonas</italic></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">2 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">UTI</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic></td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">11 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Klebsiella</italic></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">11 days</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">BSI UTI</td><td align="center" rowspan="1" colspan="1"><italic>Klebsiella Candida</italic></td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">28 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Acinetobacteria</italic></td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Ampicillin + cefotaxime</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Pseudomonas</italic></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">UTI Tissue</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic> MRCNS</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">14 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>E Coli</italic></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">10 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">UTI</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">4.5 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">UTI</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">Ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Exitus</td><td align="center" rowspan="1" colspan="1">Exitus</td></tr><tr><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">21 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">UTI</td><td align="center" rowspan="1" colspan="1"><italic>Candida</italic></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">7 months</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Stenotrophomonas</italic></td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Cefazoline</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr><tr><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">8 days</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">RTI</td><td align="center" rowspan="1" colspan="1"><italic>Klebsiella</italic></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">ampicillin + Cefotaxime</td><td align="center" rowspan="1" colspan="1">Survived</td><td align="center" rowspan="1" colspan="1">Discharged</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>BSI=blood stream infection; RTI=respiratory tract infection; UTI=urinary
tract infection; MRCNS=meticillin-resistant coagulase negative
<italic>staphylococcus</italic>; MSCNS=meticillin-sensitive
coagulase negative <italic>staphylococcus</italic>;
MSSA=meticillin-sensitive <italic>staphylococcus aureus</italic></p></fn></table-wrap-foot></table-wrap><p>Empiric cefazolin treatment was started in 41 patients and ampicillin-cefotaxime
therapy in 14 patients. Ten patients received different combinations of antibiotics
due to infections reported before ECMO support (four patients received vancomycin
and meropenem, two patients received vancomycin and ceftriaxone, two patients
received ceftriaxone, and two patients received sulbactam-ampicillin). One patient
received no antibiotics before ECMO support.</p><p>Gram-negative bacteria accounted for 44.1% (15/34), Gram-positive bacteria for 26.5%
(9/34), and <italic>Candida</italic> 29.4% (10/34) of the total culture-positive
pathogens. <italic>Candida</italic> was the most common isolate (29.4%; 10/34) in
the ECMO patient population followed by species of <italic>Coagulase-negative
Staphylococci</italic> (17.6%; 6/34), <italic>Klebsiella</italic> (14.7%; 5/34),
<italic>Pseudomonas</italic> (8.8%; 3/34), <italic>Acinetobacter</italic> (8.8%;
3/34), <italic>Stenotrophomonas maltophilia</italic> (5.9%; 2/34),
<italic>Staphylococcus aureus</italic> (2.9%; 1/34),
<italic>Micrococcus</italic> (2.9%; 1/34), <italic>Corynebacterium
bovis</italic> (2.9%; 1/34), <italic>Enterobacter cloaca</italic> (2.9%; 1/34),
and <italic>Escherichia coli</italic> (2.9% (1/34). The subspecies were
<italic>Candida Albicans</italic> in eight patients and <italic>Candida
Parapsilosis</italic> in the remaining two patients.</p><p>ECMO cannulations were performed through the chest in 60 patients, from the neck in
four patients, and from the neck and groin in two patients. No statistically
significant difference was found between the cannulation sites as means of infection
(<italic>P</italic>=0.925) (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>The characteristics of cannulation sites of infected and non-infected
patients.</p></caption><graphic xlink:href="rbccv-32-06-0468-g01"/></fig>
</p><p>The chest was left open in 61 patients, the skin was closed with silastic patch or
primarily in 37 and 24 patients, respectively. Culture-positive infections were
observed in 14 of the 24 skin primarily-closed patients (58.3%), but only in 11 of
37 skin patchclosed patients (29.7%). The results of ECMO patients who had skin
patch-closed and primarily closed were demonstrated in <xref ref-type="table" rid="t3">Table 3</xref>. The age and infection rates of the skin patch-closed
patients were found significantly lower although the risk categories were
significantly higher; the ECMO and mechanical ventilation durations and ICU stay
were significantly prolonged in skin primarily-closed patients
(<italic>P</italic>&#x0003c; 0.05).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of patient characteristics with skin patch-closed and primarily
closed.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Skin-patch closed (n=37)</th><th align="center" rowspan="1" colspan="1">Skin-primarily closed (n=24)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Overall survival</td><td align="center" rowspan="1" colspan="1">10 (27%)</td><td align="center" rowspan="1" colspan="1">11 (46%)</td><td align="center" rowspan="1" colspan="1">0.171</td></tr><tr><td align="left" rowspan="1" colspan="1">ECMO survival</td><td align="center" rowspan="1" colspan="1">23 (62%)</td><td align="center" rowspan="1" colspan="1">20 (83%)</td><td align="center" rowspan="1" colspan="1">0.090</td></tr><tr><td align="left" rowspan="1" colspan="1">Risk classification (O'Brian)</td><td align="center" rowspan="1" colspan="1">4 (1-5)</td><td align="center" rowspan="1" colspan="1">3 (1-5)</td><td align="center" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" rowspan="1" colspan="1">Infected/noninfected</td><td align="center" rowspan="1" colspan="1">26/11</td><td align="center" rowspan="1" colspan="1">14/10</td><td align="center" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" rowspan="1" colspan="1">AFR positive/negative</td><td align="center" rowspan="1" colspan="1">23/14</td><td align="center" rowspan="1" colspan="1">14/10</td><td align="center" rowspan="1" colspan="1">0.790</td></tr><tr><td align="left" rowspan="1" colspan="1">Multiple revisions</td><td align="center" rowspan="1" colspan="1">22 (59%)</td><td align="center" rowspan="1" colspan="1">16 (67%)</td><td align="center" rowspan="1" colspan="1">0.601</td></tr><tr><td align="left" rowspan="1" colspan="1">Peritoneal dialysis</td><td align="center" rowspan="1" colspan="1">8 (21%)</td><td align="center" rowspan="1" colspan="1">6 (25%)</td><td align="center" rowspan="1" colspan="1">0.765</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemodialysis</td><td align="center" rowspan="1" colspan="1">13 (35%)</td><td align="center" rowspan="1" colspan="1">10 (42%)</td><td align="center" rowspan="1" colspan="1">0.787</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (month)</td><td align="center" rowspan="1" colspan="1">1.5 (0.1-17)</td><td align="center" rowspan="1" colspan="1">7 (0.1-108)</td><td align="center" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (male/female)</td><td align="center" rowspan="1" colspan="1">20/17</td><td align="center" rowspan="1" colspan="1">15/9</td><td align="center" rowspan="1" colspan="1">0.600</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative ECMO (n)</td><td align="center" rowspan="1" colspan="1">36 (97%)</td><td align="center" rowspan="1" colspan="1">22 (92%)</td><td align="center" rowspan="1" colspan="1">0.556</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ECMO (day)</td><td align="center" rowspan="1" colspan="1">3 (1-8)</td><td align="center" rowspan="1" colspan="1">4.5 (1-13)</td><td align="center" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" rowspan="1" colspan="1">pH</td><td align="center" rowspan="1" colspan="1">7.18 (6.9-7.4)</td><td align="center" rowspan="1" colspan="1">7.19 (6.7-7.5)</td><td align="center" rowspan="1" colspan="1">0.532</td></tr><tr><td align="left" rowspan="1" colspan="1">Lactate (mmol/L)</td><td align="center" rowspan="1" colspan="1">10 (1.6-24)</td><td align="center" rowspan="1" colspan="1">9.3 (2.2-29)</td><td align="center" rowspan="1" colspan="1">0.727</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mg/dl)</td><td align="center" rowspan="1" colspan="1">16.5 (2-40)</td><td align="center" rowspan="1" colspan="1">14 (2-38)</td><td align="center" rowspan="1" colspan="1">0.372</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ICU stay (day)</td><td align="center" rowspan="1" colspan="1">11 (2-114)</td><td align="center" rowspan="1" colspan="1">21 (4-90)</td><td align="center" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ventilation (day)</td><td align="center" rowspan="1" colspan="1">9 (1-114)</td><td align="center" rowspan="1" colspan="1">18.5 (4-66)</td><td align="center" rowspan="1" colspan="1">0.040</td></tr></tbody></table></table-wrap><p>Forty patients were re-operated for bleeding at least once and had been supported by
excessive blood products during ECMO where 19 (47.5%) of them had culture-positive
infections. In terms of infectious outcomes, no statistically significant difference
of culture positivity rates was found between the patients with high rate of
bleeding and others (<italic>P</italic>=0.322).</p><p>In comparison with Medos Deltastream<sup>&#x000ae;</sup> DP2 and DP3 systems (25
patient <italic>vs.</italic> 41 patients) in terms of infectious outcomes, no
statistically significant difference of culture positivity rates was found (32%, DP2
<italic>vs.</italic> 41%, DP3, <italic>P</italic>&#x0003e;0.05).</p><p>When the infected and non-infected patient groups were compared in univariate
analysis, prolonged ICU stay, duration of ventilation, and duration of ECMO were
associated with the development of nosocomial infection in patients who received
ECMO support (<italic>P</italic>=0.045, <italic>P</italic>=0.030,
<italic>P</italic>=0.040, respectively). However, multivariate logistic regression
analysis revealed that only the duration of ECMO was an independent risk factor for
nosocomial infections in patients who received ECMO support (odds ratio:1.318; 95%
CI: 1.066-1.63; <italic>P</italic>=0.011). The ratio of patients who were
successfully weaned and discharged were not different between infected and
uninfected patients (<italic>P</italic>=0.424, <italic>P</italic>=0.435;
respectively).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this study, the characteristics and frequency of nosocomial infections associated
with ECMO support in pediatric cardiac patients were described, who are mostly
postoperative in a government hospital with a high surgical volume in a developing
country.</p><p>ECMO has been increasingly used in postoperative pediatric cardiac patients who have
inability to wean from cardiopulmonary bypass and have certain risk factors such as
infection/sepsis, bleeding, neurologic sequela, etc. The reported rate of infection
in these patients varies between 3.5% and 45% in the literature, which might be due
to different study designs<sup>[<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>In 2010, Extracorporeal Life Support Organization (ELSO)<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> reported that 18.7% of all pediatric respiratory
ECMO cases were complicated by culture-proven infections whereas in 2011 ELSO Task
Force on Infections and ECMO<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>
reported a prevalence of 13.7% and a rate of 20.7/1000 ECMO days for culture-proven
infections acquired during ECMO in the pediatric cardiac patient population.</p><p>Around 42% (28/66) of our patients experienced at least one nosocomial infection
during ECMO support with a nosocomial infection rate of 116.2/1000 ECMO days. As
emphasized in many studies<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>, the ECMO population in pre/postoperative cardiac failure or
arrest, such as the patient population in our study, are among the most critically
ill patients.</p><p>These patients were also exposed to invasive procedures before and during ECMO, and
thus, broad-spectrum antibiotics were frequently prescribed. In addition, the
patients required prolonged use of endotracheal intubation tubes, central venous
lines, urinary catheters along with the deleterious effects of cardiac surgery.
Moreover, entry into the ECMO circuit for laboratory evaluations or for
intravascular infusions increases the entry of colonized organisms in the
bloodstream, which contributes to the high rate of infections in these patients. The
reported decrease in the number and function of white blood cells in ECMO patients
with an altered immune response after cardiopulmonary bypass might also add to the
increased susceptibility to infections<sup>[<xref rid="r11" ref-type="bibr">11</xref>-<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>Prolonged ECMO support, ECMO support for cardiac disease in particular apart from
other reasons for ECMO, and requiring ECMO support with an open chest were reported
as risk factors for the development of infection and especially closed
<italic>versus</italic> open chest was reported to be protective in cardiac
patients<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Since nearly all of our patients required ECMO with an open chest, we started to
close the skin primarily of these patients during ECMO support in our clinic.
However, when we evaluated the culture-positive infection difference between the
skin-primarily closed and patch-closed patients, we found that the culture-positive
infection rates were not lower in the skin primarily-closed group as expected.
Higher operative risk categories and early death rates of skin patch-closed ECMO
patients (73% of skin patch-closed <italic>vs.</italic> 54% of the skin
primarilyclosed patients died) might lead to underestimation of the diagnosis of
infection in these patients. Besides prolonged ICU, mechanical ventilation and ECMO
durations along with although not significant higher revision rates in skin
primarilyclosed patients might cause infection rates higher than reported rates
previously. Finally as not only BSI or mediastinitis but allcause infection rates of
ECMO patients were demonstrated here, it would not be wise to explain infection of
other sites only with the type of skin closure.</p><p>A longer duration of post-ECMO ventilation support in patients with culture-proven
infection is another finding in our study in accordance with Bizarro et
al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> and Meyer et
al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> which was also
reported to be a predictor for mortality for patients on ECMO support<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>Various reports have demonstrated different microorganisms cultured from patients on
ECMO support<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>. <italic>Coagulase-negative Staphylococci,
Candida spp., Pseudomonas Aeruginosa</italic> were three of the reported
microorganisms responsible for the majority of positive cultures obtained from
patients on ECMO support in the ELSO registry<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>, and <italic>Candida spp</italic>. was the most common
cause in pediatric and adult age groups and the second most common agent in
neonates.</p><p><italic>Candida spp., Coagulase-negative Staphylococci, Klebsiella, and
Pseudomonas</italic> were the most common isolates in our study.
<italic>Candida</italic> species reported to be responsible for the majority of
cases in pediatric ECMO patients were the most common isolated agent in our study in
accordance with most studies<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>. The high prevalence of fungemia in
ECMO patients might be due to the high severity of illness and longstanding use of
wide-spectrum antibiotics before and during ECMO support<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Urinary tract infections due to
<italic>Candida</italic> should be noted as an important part of nosocomial
infections on ECMO support that has been demonstrated by other authors and
highlighted in this study<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>. <italic>Candida
spp.</italic> should be considered during an antimicrobial regimen selection
when an infection is suspected in a patient on ECMO support.</p><p>A web-based survey<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> of ELSO
responses from 132 ELSO centers demonstrated that most centers administer antibiotic
prophylaxis (mostly antibacterial) and almost half have a standardized protocol. Our
institution does not have a standardized protocol for antibiotic prophylaxis, and
our high infection prevalence might be partly due to being a new center with limited
but increasing experience and a lack of standardized protocols.</p><p>In the pediatric population, ECMO has been widely used after cardiac surgery with an
overall reported survival rate of 40-50% in different studies<sup>[<xref rid="r22" ref-type="bibr">22</xref>-<xref rid="r26" ref-type="bibr">26</xref>]</sup>. Although our ECMO survival was 68.2%, which is within the
range reported by other studies<sup>[<xref rid="r27" ref-type="bibr">27</xref>,<xref rid="r28" ref-type="bibr">28</xref>]</sup>, the overall survival rate was
33.3%. The overall survival rate improved when the ECMO patients were evaluated in
the means of years. The 24% overall survival in 2011-2012 increased to 39% in
20132014 following the switch to the DP3 system from the DP2 system after November
2012. Although improved, our overall survival rate was still lower than other
reported rates<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>. No improvement
in the culture positivity rates of ECMO patients was found between DP2 and DP3
systems. Several predictors of mortality were inconsistently identified from
different studies, including cardiac arrest before ECMO, length of mechanical
ventilation, infection/sepsis on ECMO, and duration of ECMO exceeding 8-10
days<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</sup>. Besides in a study of 56 ECMO patients with congenital
heart disease from Brazil, Miana et al.<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup> reported that after the ECMO program implementation with
investment in training and equipment increased the probability of postcardiotomy
ECMO weaning and survival. This low overall survival rate in our study might be due
to induction of ECMO support for extended e-CPR or irreversible cardiac failure
especially in the beginning period of ECMO support at our institution in 20112012
and partly due to factors such as infection on ECMO and increased length of
mechanical ventilation.</p><sec><title>Limitation</title><p>This study has some limitations. Firstly, it was limited by its retrospective
nature, data were collected by chart review and some laboratory data such as
lactate or CRP levels were not available for the entire cohort. Secondly, our
center is a tertiary cardiac center with a wide referral base for complex
cardiac surgeries and the evaluation of patients were from a single center.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, ECMO is a life-saving modality in perioperative cardiac patients who
have already increased risk for nosocomial infections. As a result, the only
independent factor associated with nosocomial infection was prolonged ECMO support
and although it was reported vice versa, the type of closure of skin did not have a
substantial protective effect for infection in cardiac ECMO patients alone. The
correction of the underlying process leading to ECMO support and shortening the
length of ECMO duration together with stricter application of ECMO indications would
be the best to prevent nosocomial infection in ECMO patients.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PA</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition of data;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">TK</td><td align="left" rowspan="1" colspan="1">Acquisition of data; drafting the paper; approval of
the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">EO</td><td align="left" rowspan="1" colspan="1">Analysis and interpretation of data; drafting the
paper; revising the paper; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">OY</td><td align="left" rowspan="1" colspan="1">Interpretation of data; revising the paper; approval of
the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">SO</td><td align="left" rowspan="1" colspan="1">Analysis and interpretation of data; drafting the
paper; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">YE</td><td align="left" rowspan="1" colspan="1">Interpretation of data; critical revising the work;
approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">SH</td><td align="left" rowspan="1" colspan="1">Interpretation of data; revising the paper; approval of
the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">Interpretation of data; revising the paper; approval of
the final version</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="financial-disclosure"><p>This study was carried out at Istanbul Saglik Bilimleri University Istanbul
Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Education and Research
Hospital, Istanbul, Turkey.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENTS</title><p>This paper was accepted to be presented as a poster in the 49<sup>th</sup> Annual
Meeting of the Association for European Paediatric and Congenital Cardiology in
Praque, in 2015.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bistrussu</surname><given-names>S</given-names></name><name><surname>Beeton</surname><given-names>A</given-names></name><name><surname>Castaldo</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>I</given-names></name><name><surname>Tuleu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Are extracorporeal membrane oxygenation circuits that are primed
with plasmalyte and stored a likely source of
&#x00131;nfection?</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><issue>8</issue><fpage>3906</fpage><lpage>3906</lpage><pub-id pub-id-type="pmid">15297564</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bizzarro</surname><given-names>MJ</given-names></name><name><surname>Conrad</surname><given-names>SA</given-names></name><name><surname>Kaufman</surname><given-names>DA</given-names></name><name><surname>Rycus</surname><given-names>P</given-names></name><collab>Extracorporeal Life Support Organization Task Force on Infections,
Extracorporeal Membrane Oxygenation</collab></person-group><article-title>Infections acquired during extracorporeal membrane oxygenation in
neonates, children, and adults</article-title><source>Pediatr Crit Care Med</source><year>2011</year><volume>12</volume><issue>3</issue><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">20495508</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KL</given-names></name><name><surname>Ridout</surname><given-names>DA</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Dodkins</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>LC</given-names></name><name><surname>O'Callaghan</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Healthcare-associated infection in pediatric patients on
extracorporeal life support: the role of multidisciplinary
surveillance</article-title><source>Pediatr Crit Care Med</source><year>2006</year><volume>7</volume><issue>6</issue><fpage>546</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">17006389</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>JM</given-names></name><name><surname>Schutze</surname><given-names>GE</given-names></name><name><surname>Heulitt</surname><given-names>MJ</given-names></name><name><surname>Simpson</surname><given-names>PM</given-names></name><name><surname>Taylor</surname><given-names>BJ</given-names></name></person-group><article-title>Nosocomial infections during extracorporeal membrane
oxygenation</article-title><source>Intensive Care Med</source><year>2001</year><volume>27</volume><issue>8</issue><fpage>1247</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">11511935</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horan</surname><given-names>TC</given-names></name><name><surname>Andrus</surname><given-names>M</given-names></name><name><surname>Dudeck</surname><given-names>MA</given-names></name></person-group><article-title>CDC/NHSN surveillance definition of health care-associated
infection and criteria for specific types of infections in the acute care
setting</article-title><source>Am J Infect Control</source><year>2008</year><volume>36</volume><issue>5</issue><fpage>309</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">18538699</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>MS</given-names></name><name><surname>Chiu</surname><given-names>KM</given-names></name><name><surname>Huang</surname><given-names>YT</given-names></name><name><surname>Kao</surname><given-names>KL</given-names></name><name><surname>Chu</surname><given-names>SH</given-names></name><name><surname>Liao</surname><given-names>CH</given-names></name></person-group><article-title>Risk factors for nosocomial infection during extracorporeal
membrane oxygenation</article-title><source>J Hosp Infect</source><year>2009</year><volume>73</volume><issue>3</issue><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">19782430</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schutze</surname><given-names>GE</given-names></name><name><surname>Heulitt</surname><given-names>MJ</given-names></name></person-group><article-title>Infections during extracorporeal life support</article-title><source>J Pediatr Surg</source><year>1995</year><volume>30</volume><issue>6</issue><fpage>809</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">7666312</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>VL</given-names></name><name><surname>Strotman</surname><given-names>JM</given-names></name><name><surname>Ross</surname><given-names>MP</given-names></name></person-group><article-title>Impact of multiple organ system dysfunction and nosocomial
infections on survival of children treated with extracorporeal membrane
oxygenation after heart surgery</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><issue>2</issue><fpage>526</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">10708195</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="book"><source>Extracorporeal Life Support Organization Registry Report: International
Summary</source><year>2010</year></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baslaim</surname><given-names>G</given-names></name><name><surname>Bashore</surname><given-names>J</given-names></name><name><surname>Al-Malki</surname><given-names>F</given-names></name><name><surname>Jamjoom</surname><given-names>A</given-names></name></person-group><article-title>Can the outcome of pediatric extracorporeal membrane oxygenation
after cardiac surgery be predicted?</article-title><source>Ann Thorac Cardiovasc Surg</source><year>2006</year><volume>12</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">16572070</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hocker</surname><given-names>JR</given-names></name><name><surname>Wellhausen</surname><given-names>SR</given-names></name><name><surname>Ward</surname><given-names>RA</given-names></name><name><surname>Simpson</surname><given-names>PM</given-names></name><name><surname>Cook</surname><given-names>LN</given-names></name></person-group><article-title>Effect of extracorporeal membrane oxygenation on leukocyte
function in neonates</article-title><source>Artif Organs</source><year>1991</year><volume>15</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">1998487</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>H</given-names></name><name><surname>Kakiuchi</surname><given-names>T</given-names></name><name><surname>Furuta</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Sudo</surname><given-names>K</given-names></name><name><surname>Furuse</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of cardiopulmonary bypass on T cells and their
subpopulations</article-title><source>Ann Thorac Surg</source><year>1987</year><volume>44</volume><issue>3</issue><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">3498449</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>F</given-names></name><name><surname>Kawazoe</surname><given-names>K</given-names></name><name><surname>Nakatani</surname><given-names>I</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cardiopulmonary bypass and cellular immunity: changes in
lymphocyte subsets and natural killer cell activity</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>55</volume><issue>3</issue><fpage>625</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">8452424</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DM</given-names></name><name><surname>Mulder</surname><given-names>DS</given-names></name><name><surname>Shennib</surname><given-names>H</given-names></name></person-group><article-title>Effect of cardiopulmonary bypass on circulating lymphocyte
function</article-title><source>Ann Thorac Surg</source><year>1992</year><volume>53</volume><issue>4</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">1532487</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>DM</given-names></name><name><surname>Jessen</surname><given-names>ME</given-names></name><name><surname>Eberhart</surname><given-names>RC</given-names></name></person-group><article-title>Neonatal extracorporeal membrane oxygenation complicated by
sepsis. Extracorporeal Life Support Organization</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>59</volume><issue>4</issue><fpage>975</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">7695427</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meliones</surname><given-names>JN</given-names></name><name><surname>Custer</surname><given-names>JR</given-names></name><name><surname>Snedecor</surname><given-names>S</given-names></name><name><surname>Moler</surname><given-names>FW</given-names></name><name><surname>O'Rourke</surname><given-names>PP</given-names></name><name><surname>Delius</surname><given-names>RE</given-names></name></person-group><article-title>Extracorporeal life support for cardiac assist in pediatric
patients. Review of ELSO Registry data</article-title><source>Circulation</source><year>1991</year><volume>84</volume><issue>5 Suppl.</issue><fpage>III168</fpage><lpage>III172</lpage><pub-id pub-id-type="pmid">1934407</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieri</surname><given-names>M</given-names></name><name><surname>Greco</surname><given-names>T</given-names></name><name><surname>Scandroglio</surname><given-names>A</given-names></name><name><surname>De Bonis</surname><given-names>M</given-names></name><name><surname>Maj</surname><given-names>G</given-names></name><name><surname>Fumagalli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Role of serum biomarkers in the diagnosis of infection in
patients undergoing extracorporeal membrane oxygenation</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><issue>Suppl 1</issue><fpage>26</fpage><lpage>26</lpage></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidron</surname><given-names>AI</given-names></name><name><surname>Edwards</surname><given-names>JR</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Horan</surname><given-names>TC</given-names></name><name><surname>Sievert</surname><given-names>DM</given-names></name><name><surname>Pollock</surname><given-names>DA</given-names></name><etal/></person-group><article-title>National Healthcare Safety Network Team; Participating National
Healthcare Safety Network Facilities. NHSN annual update:
antimicrobial-resistant pathogens associated with healthcare-associated
infections: annual summary of data reported to the National Healthcare
Safety Network at the Centers for Disease Control and Prevention,
2006-2007</article-title><source>Infect Control Hosp Epidemiol</source><year>2008</year><volume>29</volume><issue>11</issue><fpage>996</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">18947320</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubron</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Pilcher</surname><given-names>D</given-names></name><name><surname>Leong</surname><given-names>T</given-names></name><name><surname>Magrin</surname><given-names>G</given-names></name><name><surname>Cooper</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Infections acquired by adults who receive extracorporeal membrane
oxygenation: risk factors and outcome</article-title><source>Infect Control Hosp Epidemiol</source><year>2013</year><volume>34</volume><issue>1</issue><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">23221189</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffin</surname><given-names>SE</given-names></name><name><surname>Bell</surname><given-names>LM</given-names></name><name><surname>Manning</surname><given-names>ML</given-names></name><name><surname>Polin</surname><given-names>R</given-names></name></person-group><article-title>Nosocomial &#x00131;nfections in neonates receiving extracorporeal
membrane oxygenation</article-title><source>Infect Control Hosp Epidemiol</source><year>1997</year><volume>18</volume><issue>2</issue><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">9120249</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>LS</given-names></name><name><surname>Fleming</surname><given-names>GM</given-names></name><name><surname>Escamilla</surname><given-names>RJ</given-names></name><name><surname>Lew</surname><given-names>DF</given-names></name><name><surname>Lally</surname><given-names>KP</given-names></name></person-group><article-title>Antimicrobial prophylaxis and infection surveillance in
extracorporeal membrane oxygenation patients: a multi-institutional survey
of practice patterns</article-title><source>ASAIO J</source><year>2011</year><volume>57</volume><issue>3</issue><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">21317768</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Thiagarajan</surname><given-names>RR</given-names></name><name><surname>Frank</surname><given-names>D</given-names></name><name><surname>Bratton</surname><given-names>SL</given-names></name></person-group><article-title>Survival after extracorporeal cardiopulmonary resuscitation in
infants and children with heart disease</article-title><source>J Thorac Cardiovasc Surg</source><year>2008</year><volume>136</volume><issue>4</issue><fpage>984</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">18954640</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinhaus</surname><given-names>L</given-names></name><name><surname>Canter</surname><given-names>C</given-names></name><name><surname>Noetzel</surname><given-names>M</given-names></name><name><surname>McAlister</surname><given-names>W</given-names></name><name><surname>Spray</surname><given-names>TL</given-names></name></person-group><article-title>Extracorporeal membrane oxygenation for circulatory support after
repair of congenital heart defects</article-title><source>Ann Thorac Surg</source><year>1989</year><volume>48</volume><issue>2</issue><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">2669646</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raithel</surname><given-names>SC</given-names></name><name><surname>Pennington</surname><given-names>DG</given-names></name><name><surname>Boegner</surname><given-names>E</given-names></name><name><surname>Fiore</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>TR</given-names></name></person-group><article-title>Extracorporeal membrane oxygenation in children after cardiac
surgery</article-title><source>Circulation</source><year>1992</year><volume>86</volume><issue>5 Suppl.</issue><fpage>II305</fpage><lpage>II310</lpage><pub-id pub-id-type="pmid">1424018</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>MD</given-names></name><name><surname>Coles</surname><given-names>J G</given-names></name><name><surname>Williams</surname><given-names>W G</given-names></name><name><surname>Rebeyka</surname><given-names>IM</given-names></name><name><surname>Trusler</surname><given-names>GA</given-names></name><name><surname>Bohn</surname><given-names>D</given-names></name><etal/></person-group><article-title>Determinants of success in pediatric cardiac patients undergoing
extracorporeal membrane oxygenation</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>60</volume><issue>1</issue><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">7598575</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>SA</given-names></name><name><surname>Rycus</surname><given-names>PT</given-names></name><name><surname>Dalton</surname><given-names>H</given-names></name></person-group><article-title>Extracorporeal Life Support Registry Report 2004</article-title><source>ASAIO J</source><year>2005</year><volume>51</volume><issue>1</issue><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15745126</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flick</surname><given-names>RP</given-names></name><name><surname>Sprung</surname><given-names>J</given-names></name><name><surname>Gleich</surname><given-names>SJ</given-names></name><name><surname>Barnes</surname><given-names>RD</given-names></name><name><surname>Warner</surname><given-names>DO</given-names></name><name><surname>Dearani</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Intraoperative extracorporeal membrane oxygenation and survival
of pediatric patients undergoing repair of congenital heart
disease</article-title><source>Paediatr Anaesth</source><year>2008</year><volume>18</volume><issue>8</issue><fpage>757</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">18544147</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Registry report of Extracorporeal Life Support Organization</collab></person-group><source>Ann Arbor: Extracorporeal Life Support Organization</source><year>1998</year></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erek</surname><given-names>E</given-names></name><name><surname>Haydin</surname><given-names>S</given-names></name><name><surname>Onan</surname><given-names>B</given-names></name><name><surname>Onan</surname><given-names>IS</given-names></name><name><surname>Yazici</surname><given-names>P</given-names></name><name><surname>Kocyigit</surname><given-names>O</given-names></name><etal/></person-group><article-title>Extracorporeal life support experiences of a new congenital heart
center in Turkey</article-title><source>Artif Organs</source><year>2013</year><volume>37</volume><issue>1</issue><fpage>E29</fpage><lpage>E34</lpage><pub-id pub-id-type="pmid">23305584</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zt&#x000fc;rk</surname><given-names>E</given-names></name><name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>O</given-names></name><name><surname>&#x000c7;ine</surname><given-names>N</given-names></name><name><surname>T&#x000fc;z&#x000fc;n</surname><given-names>B</given-names></name><name><surname>Onan</surname><given-names>S</given-names></name><name><surname>Erg&#x000fc;l</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The use of neonatal extracorporeal life support in pediatric
cardiac intensive care unit</article-title><source>J Matern Fetal Neonatal Med</source><year>2017</year><volume>30</volume><issue>12</issue><fpage>1397</fpage><lpage>1401</lpage><pub-id pub-id-type="pmid">27432486</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miana</surname><given-names>LA</given-names></name><name><surname>Caneo</surname><given-names>LF</given-names></name><name><surname>Tanamati</surname><given-names>C</given-names></name><name><surname>Penha</surname><given-names>JG</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>VA</given-names></name><name><surname>Miura</surname><given-names>N</given-names></name><etal/></person-group><article-title>Post-cardiotomy ECMO in pediatric and congenital heart surgery:
impact of team training and equipment in the results</article-title><source>Rev Bras Cir Cardiovasc</source><year>2015</year><volume>30</volume><issue>4</issue><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">27163414</pub-id></element-citation></ref></ref-list></back></article>